Starpharma Holdings Limited
(ASX:SPL) has welcomed what it describes as positive results for its lead product VivaGel, geared to preventing recurrent bacterial vaginosis.
The pharmaceutical company says Stage 2 results demonstrate the ability of VivaGel to inhibit recurrence and provide strong support to advance to Stage 3 clinical trials.
CEO Jackie Fairley says following the results Starpharma Holdings has a high degree of confidence VivaGel will move into the next phase of trials.
The company advises the commercial opportunity for recurrent bacterial vaginosis is very attractive with an estimated market of more than $1 billion.
Shares in Starpharma Holdings last traded at $1.09 before being placed into a trading halt ahead of yesterday’s announcement made after the market closed.
Starpharma Holdings booked a net loss of $1.8 million in the first half of the 2013 financial year.
